Abstract:Carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI) has become increasingly frequent threat recently, especially in the intensive care unit (ICU). High-dose tigecycline (TGC) regimen is proposed due to the limitation of treatment options. We investigated the efficacy and safety of high-dose TGC combination regimens for treating CRKP BSI. Furthermore, the risk factors for mortality were also determined. This was a single center retrospective cohort study conducted from 2014 to 2016. A total of 40 patients with nosocomial CRKP BSI admitted to the ICU were included; they were classified into two groups according to the treatment regimens with high-dose TGC (HD group) or not (non-HD group). In-hospital mortality rates and microbiologic responses from both groups were reviewed and compared. Besides, the survival and non-survival groups were compared to identify the risk factors of mortality. Twenty-three patients constituted the HD group (high-dosage TGC regimen was administered as 200mg loading dose followed by 100mg every 12h) and 17 patients constituted the non-HD group (standard dose TGC therapy as 100mg loading dose followed by 50mg every 12h and other antibiotics). The in-hospital mortality was 52.2% in the HD group and 76.5% in the non-HD group (P=.117). The Kaplan-Meier test showed significantly longer survival times in the HD group (mean: 83 days vs 28 days; P=.027). Microbiological eradication was observed in 13 patients (56.5%) in the HD group and 6 patients (36.3%) in the non-HD group (P=.184). A smaller fraction of patients in the HD group were subjected to vasoactive therapy (52.2% vs 88.2%; P=.016) compared to the non-HD group. There was no significant difference in the manifestation of adverse effects between the two groups. In the multivariate analysis, multiple organ dysfunction syndrome (MODS), vasoactive therapy, and exposure to carbapenems were regarded as the independent predictors of mortality. A therapeutic regimen consisting of a high dose of TGC was associated with significantly longer survival time and numerically lower mortality in CRKP BSI. Adverse events were not increased with the double dose therapy.

Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review

Efficacy and Safety of Tigecycline for Complicated Urinary Tract Infection: a Systematic Review

Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series

Resistance of Clinical Isolated Gram Negative Bacilli to Tigecycline

Salvage Tigecycline in High Risk Febrile Neutropenic Patients with Hematological Malignancies: a Prospective Multicenter Study.

High-dose Tigecycline for the Treatment of Nosocomial Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections A Retrospective Cohort Study

The Rapid Emergence of Tigecycline Resistance in bla KPC-2 Harboring Klebsiella pneumoniae , as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment.

Evaluation of role of Tigecycline among clinically significant multidrug resistant pathogens from a tertiary care hospital

Tigecycline : a critical safety review

Clinical efficacy and safety of tigecycline in the treatment of the infections caused by multidrug or extensively drug resistant Acinetobacter baumannii

Pharmacokinetic and pharmacodynamic evaluation of tigecycline

Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria

Tigecycline Salvage Therapy for Critically Ill Children with Multidrug-Resistant/extensively Drug-Resistant Infections after Surgery.

Clinical efficacy and adverse reactions of tigecycline in treatment of healthcare-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii

Tigecycline: a novel glycylcycline

Molecular Epidemiology and Mechanisms of Tigecycline Resistance in Clinical Isolates of Acinetobacter Baumannii from a Chinese University Hospital.

Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections

Efficacy and Safety of Tigecycline for the Treatment of Severe Infectious Diseases: an Updated Meta-Analysis of RCTs

Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections

Clinical efficacy of tigecycline combination therapy in treatment of multidrug-resistant bacteria infections in NICU patients

Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia